Codiotoxicity of anthraciclines and the possibilities of its correction

Abstract

Due to the increased effectiveness of oncology treatments, cardiovascular disease, including chronic heart failure, is a major cause of morbidity and mortality in cancer survivors, limiting their life expectancy. Screening of 4700 literary sources from the databases "Scopus", "Web of Science", "PubMed / MedLine", "The CochraneLibrary" was carried out for the keywords "anthracycline-induced cardiotoxicity", "cardiooncology", "cancer therapy-related cardiac dysfunction", "sacubitril/valsartan" for the last 10 years. The review, based on the analysis of highly cited articles, outlines the current understanding of the cardiotoxicity of anthracyclines, its mechanisms and possibilities for correction, including the use of sacubitril/valsartan.